Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexanolone in COVID-19 ARDS
NCT04537806Phase 3Terminated
- Sponsor
- Sage Therapeutics
- Start
- Dec 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexanolone in acute respiratory distress syndrome (ARDS), sponsored by Sage Therapeutics. Started Dec 2020; status: terminated.
02
Drugs
brexanolone
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04537806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537806.